The FDA released draft industry guidance for its pathway aimed at providing incentives to stimulate competition for branded drugs that have few or no generic counterparts in the marketplace. Separately, it also updated its “name and shame” list.
The FDA released draft industry guidance for its pathway aimed at providing incentives to stimulate competition for branded drugs that have few or no generic counterparts in the marketplace.
The draft guidance outlines the criteria and timing to designate a drug as a competitive generic, the process for submitting the request, the considerations for expedited development, actions the FDA might take to expedite development and review, and determining exclusivity for the generic.
A drug can move along the competitive generic therapies (CGT) pathway when there is not more than 1 approved drug in the active section of the Orange Book. The designation, set by Congress when it granted the FDA new authorities in the FDA Reauthorization Act of 2017, provides certain incentives for industry to develop generics for drugs lacking competition that have been designated as CGTs.
In a statement, FDA Commissioner Scott Gottlieb, MD, called it “a significant advancement in generic drug competition.” He also said that over the next year, additional policies to promote competition will be released, including for complex drugs.
To date, the FDA has granted more than 100 CGT designation requests, according to the FDA. Last year, between August and December, the FDA approved the first 5 abbreviated New Drug Applications (ANDAs) for generic drugs designated as CGTs.
The CGT pathway “is efficient and effective at promoting new competition. It’s also a key step in making safe and effective generic drugs available to patients quickly while helping to ensure there’s adequate competition in the market place, so patients have access to the treatments they need,” Gottlieb said.
The FDA said the designation has a number of benefits, such as:
Separately, the FDA also updated its list of companies that have restricted access to samples of small-molecule drugs for testing through the use of Risk Evaluation and Mitigation Strategies (REMS) programs or limited distribution of their products.
The so-called “name and shame” list was first unveiled in May 2018. According to the FDA, there have been 9 new inquiries listed or submitted since the list fist published.
In addition, there have been 3 new safety determination letters issued, bringing the total to 24, and 1 additional drug product (tolvaptan, sold as Jynarque) listed which had a REMS Elements to Assure Safe Use impacting distribution to potential generic competitors. Tolvaptan is used to treat low blood sodium.
The number of drug products listed rose from 51 to 54. Besides tolvaptan, the others were the antiparasite drug pyrimethamine (Daraprim) and tiopronin (Thiola), which is used to treat cystinauria.
REMS programs, which manage potential risks of a drug, have come under scrutiny as potential avenues for anticompetitive behavior in the marketplace. Some stakeholders warn that REMS programs are used by some drug makers to improperly withhold samples of products for testing by biosimilar or generic drug developers, even in cases in which the FDA has informed a drug company in writing that it will not consider provision of samples to be a violation of a REMS program.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.